MedCity News
OCTOBER 16, 2022
As society becomes more open to and reliant on these tools, it is the responsibility of technology companies, especially those tasked with assisting people’s mental health, to build and maintain artificial intelligence and machine learning models that adapt alongside societal needs.
European Pharmaceutical Review
OCTOBER 20, 2022
In recent years there has been significant development within the cell therapy field, as chimeric antigen receptor (CAR) T-cell therapy demonstrated an ability to transform the treatment of patients with haematological malignancies. Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medical Device Success
OCTOBER 17, 2022
Reading time: 2 – 4 minutes. 100 episodes! Wow! Hard to believe. Over 64,000 cumulative downloads. Thank you for all your support. And….you will have to keep listening because there is a lot more to share with you. Today we go back to value-based care from the providers viewpoint. Joseph Schulman is back for the second time. Joe is the Senior Vice President Enterprise Data and Chief of Information Intelligence at Northwell Health.
PharmaTimes
OCTOBER 18, 2022
First treatment in 30 years to improve second-line treatment of DLBCL
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
OCTOBER 17, 2022
President Biden continues to center his pre-midterm speeches around the issue of prescription drug costs, […].
European Pharmaceutical Review
OCTOBER 17, 2022
Novartis announced that The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Pluvicto ® radioligand therapy for treatment of patients with prostate cancer. Pluvicto combines a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope (in this case lutetium-177).
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTimes
OCTOBER 18, 2022
Therapy is based on ACD856's indicative disease modifying effects against the condition
MedCity News
OCTOBER 19, 2022
The healthcare industry has been reported as the second most targeted industry from cyberattacks. Following the business […].
PharmaVoice
OCTOBER 19, 2022
Major recent trial flops and what they mean for companies, patients and the industry.
pharmaphorum
OCTOBER 20, 2022
And the LIVE coverage continues as we head into Day Two… This day is set to hold even more points of interest, with the demonstration ‘CX innovation: building experiences that work for customers’ (moderated by Healthware Group’s global head of digital strategy and customer engagement Yannick Valenti), as well as the masterclass ‘How to maximise learning science to affect behaviour change’ with Meducate Global’s president, Lawrence Sherman, and MD of Healthware MedComms & SWM, Francis M
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTimes
OCTOBER 17, 2022
Demonstrators will demand hundreds of millions of pounds ‘missing’ from ME research
MedCity News
OCTOBER 16, 2022
With so much supporting data and real-world success, it is time for catheter ablation to become a routine treatment option for patients suffering from arrhythmias.
Pharmaceutical Technology
OCTOBER 19, 2022
Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 for each share in cash. The deal comprises an acquisition value of $12.50 for each share in cash payable at closing along with one non-tradeable contingent value right per share (CVR) of up to another $3 in cash.
pharmaphorum
OCTOBER 17, 2022
When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed.
PharmaTimes
OCTOBER 19, 2022
Therapy treats refractory chronic immune thrombocytopenia and is available across UK
MedCity News
OCTOBER 17, 2022
Eyenuk, a company that makes technology for eye screenings, raised $26 million in a Series A funding round, bringing its total funding to more than $43 million. Research shows that the company’s AI system is more accurate in detecting diabetic retinopathy than a clinical examination from a general ophthalmologist or a retina specialist.
PharmaVoice
OCTOBER 21, 2022
C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.
Pharmaceutical Technology
OCTOBER 21, 2022
Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers. On concluding this trial, Roche will gain the right to develop and market the licenced products across various indications, contingent on approval.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaTimes
OCTOBER 19, 2022
Therapy showed faster clinical recovery for combined treatment groups
MedCity News
OCTOBER 16, 2022
NeuroFlow, a Philadelphia-based provider of behavioral health integration software, recently raised $25 million in growth capital. The startup differentiates itself from the sea of mental health-focused startups in the digital health world because of its ability to combine effective patient engagement technology with decision support tools for clinical staff, according to COO Adam Pardes.
PharmaVoice
OCTOBER 18, 2022
Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.
European Pharmaceutical Review
OCTOBER 18, 2022
Kite announced that the European Commission (EC) has approved the use of cell therapy Yescarta ® for treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), who relapse within 12 months or are refractory to, first-line chemoimmunotherapy. The approval is based on results from the Phase III ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus standard of care (SOC) in this patient population.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
OCTOBER 17, 2022
Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. Elinzanetant is already being tested in the OASIS trials for VMS associated with menopause – an indication in which Bayer is in a head-to-head race with Astellas and its fezolinetant drug candidate – and breast cancer could represent a sizeable additional patient population for the drug.
MedCity News
OCTOBER 17, 2022
Healthcare organizations must ensure they have a data-literate workforce that is confident in using the data and is empowered in using it to make decisions. Here are some best practices that hospitals can implement to better empower their employees to make data-driven decisions.
Medgadget
OCTOBER 19, 2022
Researchers at Hokkaido University in Japan have developed a biomarker test for Alzheimer’s disease that detects amyloid ? binding exosomes in a blood sample. While amyloid ? plaques in the brain are characteristic of Alzheimer’s, these researchers have previously reported that amyloid ? build-up in the brain is associated with an increase in amyloid ?
PharmaVoice
OCTOBER 20, 2022
The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
European Pharmaceutical Review
OCTOBER 20, 2022
Apogenix , a biopharmaceutical company developing next generation immunotherapeutics, announced that asunercept showed statistically significant benefits for hospitalised COVID-19 patients in the ASUNCTIS trial. Apogenix’s lead immunotherapy candidate, asunercept is a fully human fusion protein, consisting of the CD95 receptor and an IgG1 antibody. It is being developed for the treatment of solid tumours, haematological malignancies and viral infections such as COVID-19.
MedCity News
OCTOBER 16, 2022
Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.
pharmaphorum
OCTOBER 19, 2022
Frontiers Health 2022 in Milan is LIVE! Opening Day One will be Healthware Group’s CEO and founder Roberto Ascione and WTF Health’s founder and host Jessica DaMassa. The day’s keynote addresses will include ‘The H is for humanity’ by MD of Taliossa Tony Estrella and founder and trustee of Rachel’s House Lynna Chandra, as well as ‘Creative disruption in delivering novel VR solutions in pain: evidence, teamwork, and delivery’ by Christopher Eccleston, professor of medical psychology at the U
Pharmaceutical Technology
OCTOBER 18, 2022
A new study identifies a novel cerebrospinal fluid biomarker for Parkinson’s disease, expanding the scope of possible drug targets. Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in cerebrospinal fluid (CSF) between healthy individuals and Parkinson’s patients. There is potential that these structural changes could allow for a new method of differentiating different disease subtypes, thus expanding the scope
Expert insights. Personalized for you.
145 
Let's personalize your content